- Previous Close
1.4700 - Open
1.4800 - Bid --
- Ask --
- Day's Range
1.4450 - 1.5000 - 52 Week Range
0.6300 - 1.5100 - Volume
1,204,120 - Avg. Volume
1,281,745 - Market Cap (intraday)
63.22M - Beta (5Y Monthly) 1.25
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6600 - Earnings Date Apr 2, 2025 - Apr 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.50
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
www.achillestx.comRecent News: ACHL
View MorePerformance Overview: ACHL
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACHL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACHL
View MoreValuation Measures
Market Cap
65.42M
Enterprise Value
-17.01M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.61
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.17%
Return on Equity (ttm)
-52.12%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-66.88M
Diluted EPS (ttm)
-1.6600
Balance Sheet and Cash Flow
Total Cash (mrq)
86.05M
Total Debt/Equity (mrq)
3.51%
Levered Free Cash Flow (ttm)
-44.71M